Sickle Cell Disease

Health Resources Hub / Blood Health /

Sickle Cell Disease

Overview

Tips and Extra Resources

OverviewOverview

Sickle Cell Disease (SCD) is a group of inherited red blood cell disorders. Healthy red blood cells are round and they move efficiently through the blood vessels to carry oxygen to all parts of the body. In SCD, red blood cells become hard and sticky and look like a C-shaped farm tool called a "sickle." These sickle cells can get stuck in small blood vessels, which can slow or block blood flow and oxygen to parts of the body.

Sickle Cell Disease primarily affects individuals of African, Mediterranean, Middle Eastern, and Indian ancestry. However, it can affect individuals of any ethnic background. The condition can lead to severe pain, anemia, infection, and various complications.

Risk Factors

Several risk factors can increase the likelihood of developing SCD. An individual must inherit two sickle cell genes, one from each parent, to have the disease.

The primary risk factors include:

Family history: If both parents carry the sickle cell gene, the risk of the offspring having SCD is increased.
Ethnicity: Individuals of African, Mediterranean, Middle Eastern, and Indian descent are at higher risk of carrying the gene for SCD.

Causes

SCD is caused by a genetic mutation in the hemoglobin gene. Hemoglobin is the protein in red blood cells that carries oxygen. The mutation leads to the production of abnormal hemoglobin called hemoglobin S. When hemoglobin S releases oxygen, it causes red blood cells to become rigid and take on the sickle shape.

The disease is inherited in an autosomal recessive pattern, meaning that both copies of the gene in each cell have mutations. Parents who carry one copy of the sickle cell gene are known as carriers or have a "sickle cell trait" but usually do not show symptoms.

Signs and Symptoms

The signs and symptoms of Sickle Cell Disease can vary widely among individuals. Common symptoms include:

Episodes of pain (crises): Painful episodes occur when sickle cells block blood flow, often affecting the bones, lungs, abdomen, and joints.
Anemia: Sickle cells break apart easily and die, leading to a constant shortage of red blood cells.
Swelling of hands and feet: Caused by sickle-shaped red blood cells blocking blood flow to the extremities.
Frequent infections: Sickle cells can damage the spleen, an organ that fights infection.

Diagnosis and Tests

Diagnosis of Sickle Cell Disease often begins with a blood test. Early diagnosis is crucial for managing and treating the condition effectively.

Common diagnostic tests include:

Newborn screening: Blood tests performed at birth can identify SCD before symptoms appear.
Hemoglobin electrophoresis: This test differentiates between normal and abnormal types of hemoglobin.
Complete blood count (CBC): Evaluates the levels of red blood cells, white blood cells, and platelets in the blood.

Treatments

Treating Sickle Cell Disease focuses on relieving symptoms, preventing complications, and managing the condition over time. Although there is no cure for most individuals, treatments can improve quality of life.

Common treatments include:

Pain management: Use of over-the-counter pain relievers and prescription medications to manage pain crises.
Hydroxyurea: This medication increases the production of fetal hemoglobin, which reduces the frequency of painful sickle cell crises and the need for blood transfusions.
L-glutamine (Endari): Approved by the FDA to reduce the frequency of sickle cell crises, this amino acid is thought to help reduce oxidative damage to red blood cells.
Voxeletor: This oral medication helps improve anemia and reduce hemolysis (breakdown of red blood cells) by increasing hemoglobin levels.
Crizanlizumab (Adakveo): An intravenous infusion that helps reduce the frequency of vaso-occlusive crises (painful episodes) by preventing the adhesion of sickled red blood cells to blood vessel walls.
Blood transfusions: Transfusions increase the number of normal red blood cells and decrease the proportion of sickle cells.
Bone marrow transplant: The only potential cure, but suitable only for a small number of patients due to risks and donor matching.

Emerging treatments, such as gene therapy and newer drugs, are also being researched and hold promise for more effective management and potential cures for SCD in the future.

Recent FDA approvals for sickle cell disease (SCD) have introduced groundbreaking gene therapies that hold significant promise for patients. Two notable approvals are Casgevy and Lyfgenia, both aimed at treating individuals 12 years and older with severe SCD.

Casgevy: This therapy uses CRISPR/Cas9 gene-editing technology to increase the production of fetal hemoglobin. By modifying a specific gene that normally halts fetal hemoglobin production after birth, Casgevy enables the continued production of this more effective form of hemoglobin. The therapy involves extracting the patient’s blood cell precursors, modifying them, and then reintroducing them after a chemotherapy regimen to eliminate the faulty cells. Clinical trials showed that a single infusion of Casgevy prevented painful vaso-occlusive crises (VOCs) for at least a year in 93.5% of evaluated patients.

Lyfgenia: Developed by Bluebird Bio, Lyfgenia uses a viral vector to deliver genetic modifications to the patient’s blood stem cells, encouraging the production of healthy hemoglobin. Like Casgevy, it involves a single-dose infusion after chemotherapy to eradicate the defective blood cells. Clinical studies demonstrated that 87.5% of patients treated with Lyfgenia experienced no sickle cell events following their transplant.

These gene therapies represent significant advancements in the treatment of SCD, potentially offering a one-time cure for a condition that has traditionally required ongoing management with medications and blood transfusions.

Tips and Extra Resources

For those living with Sickle Cell Disease and their caregivers, staying informed and proactive can make a big difference. Consider the following tips: